EmailFacebookLinkedInTwitterGoogle+
Oxford Biotheraputics
About Us
About Us

Precision Cancer Therapy

Oxford BioTherapeutics is an international biotechnology company focused on developing innovative antibody drug conjugates (ADCs) to treat cancer. This new treatment approach combines a number of technologies to target cancer cells with potent cell-killing agents. Our OGAP® target discovery system – the largest of its type in the world – ‘unlocks’ the power of ADCs by providing a unique range of validated, novel antigen targets identified from a wide range of cancer types.

Through our collaborations with other leading companies in the field, such as Seattle Genetics, ImmunoGen, Medarex and Amgen, we can use the optimal combination of technologies to develop successful ADCs.

We are now advancing our portfolio of treatments into clinical testing with our development partner Menarini. In addition to this in-house ADC development, we also work with pharmaceutical companies to provide our target discovery expertise as the foundation for new cancer therapies.

Company Timeline


2013 - First in-house clinical candidate designated

2013 - Collaboration with Boehringer Ingelheim

download_pdf

2012 - $1BN R&D investment collaboration with Menarini

download_pdf

2011 - Cancer toxin collaboration with Seattle Genetics

download_pdf

2011 - Enhanced antibody partnership with BioWa

download_pdf

2007 - Antibody partnership with Amgen

download_pdf

2006 - Antibody collaboration with Medarex

download_pdf

2005 - Move to purpose-built facility

download_pdf

2004 - Company established